Traditional Chinese medicine composition for treating psoriasis as well as preparation method and application thereof

Abstract

The invention discloses a traditional Chinese medicine composition for treating psoriasis and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition is composed of ephedra, cassia twig, radix paeoniae rubra, polygonum cuspidatum, artemisia apiacea and oldenlandia diffusa. Compared with the traditional Chinese medicine composition capable of relieving psoriasis and detoxifying, the traditional Chinese medicine composition disclosed by the invention omits coptis chinensis, indigo naturalis and felwort, is simpler in prescription, and has more advantages in the aspect of improving psoriasis-like skin lesion of model mice.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating psoriasis, and a preparation method and application thereof. Background Art

[0002] Psoriasis, also widely known as "psoriasis", is a common multi-gene inherited skin disease, often manifested as localized or widespread scaly erythema or plaques. The cause of psoriasis is still unclear, but it has been identified as a combination of genetic and environmental factors. There are many types of psoriasis, the most common of which is the common type, in addition to arthropathy, pustular and erythrodermic types. The symptoms of psoriasis are diverse, mainly including red patches on the skin, usually covered with silvery-white scales, itching, burning or pain, dry, cracked skin, and even bleeding. Some patients may have joint pain, swelling, and abnormalities of the nails. Current treatments include drug therapy, phototherapy, and traditional Chinese medicine. Although the disease cannot be completely cured at this stage, active treatment can significantly reduce skin lesions or promote recovery, avoid serious complications, and improve the quality of life of patients.

[0003] Qin Yeping, Dai Dan, Xiao Xue, Song Ping. Kaixuan Jiedu Recipe improves the symptoms of imiquimod-induced psoriasis-like mice by regulating S1P levels [J]. Journal of Jiangsu University (Medical Edition), 2023, 33(2): 118-125. It is disclosed that Kaixuan Jiedu Recipe can improve the symptoms and signs of psoriasis mice in many aspects, such as improving splenomegaly, thymic atrophy, capillary hyperplasia, reducing the degree of epidermal hyperplasia, repairing the skin barrier, and reducing the expression of local inflammatory factors; on the other hand, the drug can not only regulate S1P expression, but also regulate the expression level of S1PR at the mRNA level. The S1P / S1PR pathway is very likely to be a potential target of Kaixuan Jiedu Recipe, and S1P / S1PR plays an important role in inflammatory signaling pathways, skin cell proliferation, and skin barrier. However, the document only discloses the composition of Kaixuan Jiedu Recipe, and does not disclose the drug ratio, let alone optimize the drug ratio.

[0004] In view of this, in order to solve the deficiencies of the prior art, the present invention provides a Chinese medicine composition for treating psoriasis, and a preparation method and application thereof. The Chinese medicine composition disclosed in the present invention can be used to prepare drugs for treating psoriasis. Summary of the invention

[0005] The purpose of the present invention is to overcome the deficiencies in previous studies, provide a Chinese medicine composition for treating psoriasis and a preparation method and application thereof, give full play to the efficacy of Chinese medicine, and effectively solve the problem of medication for the treatment of psoriasis.

[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0007] On the one hand, the present invention provides a traditional Chinese medicine composition for treating psoriasis, which is composed of ephedra, cinnamon twig, red peony root, polygonum cuspidatum, artemisia annua, and oldenlandia diffusa.

[0008] Preferably, the traditional Chinese medicine composition consists of 1-12 parts of ephedra, 3-18 parts of cassia twig, 3-18 parts of red peony root, 5-20 parts of knotweed, 5-40 parts of artemisia annua, and 5-40 parts of oldenlandia diffusa by weight.

[0009] Further preferably, the Chinese medicine composition consists of 6 parts of ephedra, 9 parts of cinnamon twig, 9 parts of red peony root, 10 parts of knotweed, 20 parts of artemisia annua, and 20 parts of oldenlandia diffusa in parts by weight.

[0010] In another aspect, the present invention provides a method for preparing the above-mentioned traditional Chinese medicine composition, characterized in that it comprises the following steps: taking ephedra, cinnamon twig, red peony root, polygonum cuspidatum, artemisia annua, and oldenlandia diffusa and grinding them into powder.

[0011] In yet another aspect, the present invention provides a medicine, the effective ingredients of which include the above-mentioned Chinese medicine composition.

[0012] The drug can be prepared into dosage forms such as pills, capsules, granules, oral liquids, powders, tablets, lozenges, and lozenges, and suitable drug carriers in the art can be selected for different dosage forms.

[0013] The pharmaceutical carrier used can be solid, liquid or gas. Examples of solid carriers include lactose, kaolin, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate and stearic acid. Examples of liquid carriers include syrup, peanut oil, olive oil and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

[0014] When preparing the composition for oral dosage form, any convenient pharmaceutical medium can be used. For example, water, ethanol, oil, alcohol, flavoring agent, preservative, coloring agent, etc. can be used to form oral liquid preparations, such as suspensions and solutions; while carriers, such as starch, sugars, microcrystalline cellulose, diluents, granulating agents, emulsifiers, lubricants, binders, disintegrants can be used to form oral solid preparations, such as powders, capsules and tablets. Tablets and capsules are the preferred oral dosage units using solid pharmaceutical carriers due to their ease of administration. Tablets can be coated using standard aqueous or non-aqueous techniques.

[0015] Tablets containing the Chinese medicine composition of the present invention can be prepared by tableting or molding, and one or more auxiliary ingredients or adjuvants can be used. The active ingredient can be tableted in a free-flowing form (such as powder or granules) in a suitable machine, and can be mixed with an adhesive, a lubricant, an inert diluent, a surfactant or a dispersant to prepare a tablet. Molded tablets can be molded in a suitable machine, i.e., a powdered compound mixture moistened with an inert liquid diluent. Each tablet preferably contains about 0.05 mg to about 5 g of active ingredient, and each sachet or capsule preferably contains about 0.05 mg to about 5 g of active ingredient. For example, a preparation intended for oral administration to humans may contain about 0.5 mg to about 5 g of active drug, mixed with an appropriate and convenient carrier material, which may account for about 5% to 95% of the total composition. The unit dosage form usually contains about 1 mg to about 2 g of active ingredient, usually 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.

[0016] The pharmaceutical composition suitable for parenteral administration of the present invention can be prepared as an aqueous solution or suspension of the active compound. Suitable surfactants such as hydroxypropylcellulose can be included. Dispersions can also be prepared in glycerol, liquid polyethylene glycol and oil mixtures thereof. In addition, preservatives can be added to prevent the harmful growth of microorganisms.

[0017] Medicine of the present invention can be in the form suitable for topical use, for example aerosol, cream, ointment, lotion, powder or the like. In addition, composition can be in the form suitable for transdermal administration device. Can use Chinese medicine composition of the present invention, prepare these prescriptions by conventional processing method. For example, by mixing hydrophilic material and water, and about 5wt% to about 10wt% of compound, prepare cream or ointment with required consistency.

[0018] The medicine of the present invention can be in a form suitable for rectal administration, wherein the carrier is a solid. Preferably, the mixture is made into a unit dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories can be prepared by first forming a composition containing a softened or melted carrier, followed by cooling and shaping in a mold.

[0019] In addition to the above-mentioned carrier components, the above-mentioned pharmaceutical preparations may include (if applicable) one or more additional carrier components, such as diluents, buffers, flavoring agents, adhesives, surfactants, thickeners, lubricants, preservatives (including antioxidants), etc. In addition, other excipients, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc., colorants and flavoring agents, etc., may be added. The preparation is made isotonic with the blood of the intended recipient. The components containing the Chinese medicine composition of the present invention can also be prepared in the form of powder or concentrate.

[0020] Preferably, the pharmaceutical preparation is an oral pharmaceutical preparation.

[0021] More preferably, the oral pharmaceutical preparation is any one of a decoction, a pill, a tablet, a capsule, a powder, a granule, and an oral liquid.

[0022] Finally, the present invention provides the use of the above-mentioned traditional Chinese medicine composition in the preparation of a drug for treating psoriasis.

[0023] Preferably, the psoriasis is selected from any one of psoriasis vulgaris, psoriasis arthritis, psoriasis pustularis, and psoriasis erythroderma.

[0024] More preferably, the psoriasis is psoriasis vulgaris.

[0025] Preferably, the symptoms of psoriasis include:

[0026] (1) Red patches appear on the skin, covered with silvery white scales;

[0027] (2) Itching, burning or pain of the skin;

[0028] (3) Dry, cracked or bleeding skin;

[0029] (4) Scaly skin on the scalp;

[0030] (5) The fingernails and / or toenails are pin-shaped or pitted, onycholysis, or subungual hyperkeratosis;

[0031] (6) Joint swelling.

[0032] Further preferably, the symptoms of psoriasis include:

[0033] (1) Red patches appear on the skin, covered with silvery white scales;

[0034] (2) Itching, burning or pain of the skin;

[0035] (3) Dry, cracked or bleeding skin.

[0036] Compared with the prior art, the present invention has the following beneficial effects:

[0037] Compared with the Kaixuan Jiedu prescription (composed of Artemisia annua, Polygonum cuspidatum, Oldenlandia diffusa, Coptis chinensis, Ephedra, Cinnamon twig, Indigo naturalis, and Gentiana scabra), the Chinese medicine composition disclosed in the present invention omits Coptis chinensis, Indigo naturalis, and Gentiana scabra, and the prescription is more streamlined, which has more advantages in improving psoriasis-like skin lesions in model mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The effects of Examples 1-3 and Comparative Examples 1-3 on the skin lesions of model mice.

[0039] Figure 2 The PASI scores of the back skin lesions of the blank group, model group, and Example 1-3 groups on the 6th day, where: ** , P<0.01; *** , P<0.001.

[0040] Figure 3 PASI scores of back skin lesions of mice in the blank group, model group, Example 1 group, and Comparative Example 1-3 groups on the 6th day, where: ** , P<0.01; *** , P<0.001.

[0041] Figure 4 The effects of Examples 1-3 and Comparative Examples 1-3 on the pathological manifestations of skin lesions in psoriasis model mice. DETAILED DESCRIPTION

[0042] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of protection claimed in this application, and those skilled in the art can make various changes and modifications to the invention of this application based on the disclosed content, which should also fall within the scope of protection claimed in this application.

[0043] The present invention is further described below by way of specific examples. Unless otherwise specified, the various drugs used in the examples of the present invention are obtained through conventional commercial channels.

[0044] Ephedra is the herbaceous stem of Ephedra sinica, Ephedra equisetum or Ephedra intermedia, all of the Ephedraceae family.

[0045] Cinnamon twigs are the young branches of cinnamon, a plant of the Lauraceae family.

[0046] Red peony root is the dried root of red peony root or Sichuan red peony root of the Ranunculaceae family.

[0047] Polygonum cuspidatum Sieb.et Zucc., a plant of the Polygonaceae family, is the dried rhizome and root.

[0048] Artemisia annua is the dried aerial part of Artemisia annua L., a plant of the Asteraceae family.

[0049] Hedyotis diffusa, a plant of the genus Hedyotis diffusa in the family Rubiaceae

[0050] The whole herb of Hedyotis diffusa Willd. [Oldenlandia diffusa (Willd.) Roxb.].

[0051] Example 1

[0052] The formula is as follows: 6 parts of ephedra, 9 parts of cassia twig, 9 parts of red peony root, 10 parts of knotweed, 20 parts of artemisia annua, and 20 parts of oldenlandia diffusa.

[0053] Preparation method: Take the prescribed amount of medicinal materials and grind them into powder.

[0054] Example 2

[0055] The formula is as follows: 1 part of ephedra, 3 parts of cassia twig, 18 parts of red peony root, 20 parts of knotweed, 40 parts of artemisia annua, and 40 parts of oldenlandia diffusa.

[0056] The preparation method is the same as that of Example 1.

[0057] Example 3

[0058] The formula is as follows: 12 parts of ephedra, 18 parts of cassia twig, 3 parts of red peony root, 5 parts of knotweed, 5 parts of artemisia annua, and 5 parts of oldenlandia diffusa.

[0059] The preparation method is the same as that of Example 1.

[0060] Comparative Example 1

[0061] The formula is as follows: 1 part of ephedra, 3 parts of cinnamon twig, 20 parts of knotweed, 40 parts of artemisia annua, 40 parts of oldenlandia diffusa, 6 parts of coptis root, 3 parts of indigo, and 9 parts of gentian. This formula is referenced by (Qin Yeping, Dai Dan, Xiao Xue, et al. Kaixuan Jiedu Recipe improves the symptoms of psoriasis-like mice induced by imiquimod by regulating S1P levels [J]. Journal of Jiangsu University: Medical Edition, 2023, 33(2): 118-125. DOI: 10.13312 / j.issn.1671-7783.y230038.).

[0062] The preparation method is the same as that of Example 1.

[0063] Comparative Example 2

[0064] The formula is as follows: 6 parts of ephedra and 9 parts of cinnamon twig.

[0065] The preparation method is the same as that of Example 1.

[0066] Comparative Example 3

[0067] The formula is as follows: 9 parts of red peony root, 10 parts of knotweed, 20 parts of artemisia annua, and 20 parts of oldenlandia diffusa.

[0068] The preparation method is the same as that of Example 1.

[0069] Results

[0070] 1. Experimental Materials and Methods

[0071] 1.1 Experimental Animals

[0072] Specific pathogen-free (SPF) grade C57BL / 6J mice, male, 6-8 weeks old, weighing 18-22g, a total of 48, were purchased from Beijing Weitonglihua Animal Technology Co., Ltd., license number: SCXK (Beijing) 2021-0006. Mice were raised under SPF conditions in the animal room of Guang'anmen Hospital of China Academy of Chinese Medical Sciences, and were given standard ordinary feed, environmental humidity of 55±5%, temperature controlled at 22-25℃, and light time of 12h / day. Cage, 6 per cage, a total of 8 cages, free access to food and water. The experimental protocol was approved by the Experimental Animal Ethics Committee of Guang'anmen Hospital of China Academy of Chinese Medical Sciences (approval number: IACUC-GAMH-2021-021). All experimental animal protocols were operated in accordance with the guidelines approved by the Animal Ethics Committee.

[0073] 1.2 Experimental drugs

[0074] The embodiments and comparative examples were provided by the pharmacy of Guang'anmen Hospital, China Academy of Chinese Medical Sciences; Imiquimod cream (company: 3M Health Care limited, imported drug registration certificate number: H20160079, specification: 12.5 mg / 250 mg).

[0075] 1.3 Main experimental reagents

[0076] Table 1 Main experimental reagents

[0077]

[0078]

[0079] 1.4 Experimental Methods

[0080] 1.4.1 Establishment of psoriasis mouse model

[0081] All C57BL / 6J mice in the model group were adaptively raised for one week before modeling. The hair on the back of the mice was shaved with a razor one day before modeling to form an exposed area of ​​about 2 cm × 3 cm, and then the exposed area was covered with depilatory cream. After the depilatory cream stayed on the back of the mouse for 90 seconds, a paper towel was dipped in warm water to remove the depilatory cream and the remaining hair on the back to fully expose the back skin of the mouse. After the modeling started, 62.5 mg of imiquimod cream was applied to the exposed skin at 9:00 every day, once a day, for 5 consecutive days. At the same time, 62.5 mg of vaseline was applied to the back of the blank group mice as a control.

[0082] 1.4.2 Grouping and Dosing

[0083] Gavage administration began 4 hours after modeling, and the conversion was made according to the human-mouse body surface area (1:12.3) in "Pharmacological Experimental Methodology", that is, 30.34g crude drug / kg. The specific groups are as follows:

[0084] ① Blank group: 62.5 mg of vaseline applied on the back and 0.2 mL of distilled water were gavaged;

[0085] ② Model group: 62.5 mg imiquimod cream applied on the back and 0.2 mL distilled water gavage;

[0086] ③ Example 1 group: 62.5 mg of imiquimod cream + 30.34 g of the crude drug prepared in Example 1 / kg were applied to the back and intragastrically administered, with a dosing volume of 0.2 mL;

[0087] ④ Group 2 of Example 2: 62.5 mg of imiquimod cream + 30.34 g of the crude drug prepared in Example 2 / kg were applied to the back and intragastrically administered in a volume of 0.2 mL;

[0088] ⑤ Example 3 group: 62.5 mg of imiquimod cream + 30.34 g of the crude drug prepared in Example 3 / kg was applied to the back and intragastrically administered in a volume of 0.2 mL;

[0089] ⑥Comparative Example 1 group: 62.5 mg of imiquimod cream + 30.34 g of the crude drug prepared in Comparative Example 1 / kg was applied to the back and the administration volume was 0.2 mL;

[0090] ⑦Comparative Example 2 group: 62.5 mg of imiquimod cream + 30.34 g of the crude drug prepared in Comparative Example 2 / kg was applied to the back and the administration volume was 0.2 mL;

[0091] ⑧Comparative Example 3 group: 62.5 mg of imiquimod cream + 30.34 g of the crude drug prepared in Comparative Example 3 / kg was applied to the back and intragastrically administered, with a dosing volume of 0.2 mL.

[0092] Each group of 6 mice was gavaged once a day for 5 consecutive days. The mice were weighed and the PASI score of the skin lesions was calculated before applying imiquimod cream every day, and the skin morphology on the back of the mice was recorded by photographing under consistent lighting and shooting tools.

[0093] 1.4.3. Sample collection and storage

[0094] After the mouse modeling and intervention on the 5th day, the feed was taken away and the mice were starved. The samples were collected at 8 am on the 6th day. The mice were anesthetized by intraperitoneal injection of 0.2 mL / 10 g of 0.3% sodium pentobarbital solution prepared with normal saline. After anesthesia, the whiskers of the mice were trimmed, the eyeballs were removed with tweezers, and the blood of the mice was collected with serum separation gel coagulation tubes. After the blood collection was completed, the test tubes were stored at room temperature.

[0095] The mice after blood collection were placed on a pre-sterilized foam board, and the back skin was cut with surgical scissors and transferred to PBS solution for rinsing. The skin subcutaneous tissue was placed facing up and spread on white filter paper, and photos were taken to record the subcutaneous vascular proliferation. The skin tissue was divided into 4 parts, one of which was attached to the filter paper and put into neutral formalin fixative to prevent the skin tissue from curling. The other three parts were put into marked tissue cryopreservation tubes, and after quick freezing with liquid nitrogen, they were transferred to a -80℃ refrigerator for storage.

[0096] 1.4.4 PASI score for skin lesions

[0097] On days 1-6, before modeling, fixed equipment and relatively consistent lighting conditions were used to photograph and record the changes in skin lesions on the back of mice. The PASI scoring standard was used to score the erythema (0-4 points), scaling (0-4 points), and degree of infiltration (0-4 points) of the skin lesions of mice. The sum of the three scores was the PASI score.

[0098] 1.4.5. Preparation and sectioning of histopathological wax blocks

[0099] Remove the tissues fixed for 72 hours or more from the fixative, use a scalpel to cut the tissue part to be observed, put them into the marked tissue embedding box, and dehydrate them in 75% ethanol for 2 hours → 85% ethanol for 30 minutes → 95% ethanol for 2 hours → (change liquid) 95% ethanol for 2 hours → anhydrous ethanol for 2 hours → (change liquid) anhydrous ethanol for 2 hours, and make the tissue transparent by xylene for 1.5 hours → (change liquid) xylene for 1.5 hours → (change liquid) xylene for 45 minutes. Start the wax melting cylinder of the tissue embedding machine in advance, set the parameters to 62℃ to melt the paraffin, and immerse the dehydrated and transparentized tissue in wax for 3 hours.

[0100] After the wax dipping is completed, start the embedding machine cold stage, prepare the pathological tissue wax block embedding mold in advance, open the embedding box, take out the wax-dipping tissue, drip 1 / 4 paraffin wax into the mold, use tweezers to place the tissue to be observed face up in the mold, wait for the paraffin wax in the mold to solidify slightly, quickly drip paraffin wax into the mold and buckle the bottom of the embedding box, transfer it to the cold stage, and after the wax block has solidified, transfer it from the cold stage to the room temperature laboratory operating table for demolding, and the tissue pathology wax block is completed.

[0101] Start the slide spreader in advance and set the water temperature to 55°C. Take the prepared wax block and fix it on the paraffin slicer. Turn on the air humidifier and aim at the wax block. Set it to rough trimming 20μm / time first, and set it to fine trimming after cutting the tissue. The skin tissue is 4.5μm. After the sectioning is completed, spread the tissue wax slice in the slide spreader with tweezers. When the tissue is fully stretched without wrinkles, use an ordinary slide or a high-adhesion slide to pick up the slice and dry it overnight.

[0102] 1.4.6. Eosin-Hematoxylin (HE) staining

[0103] The baking machine was set to 60℃ for 1h. After the paraffin was fully melted, the slices were placed in xylene for 10min→(change liquid) xylene for 5min→(change liquid) xylene for 5min→anhydrous ethanol for 10min→(change liquid) anhydrous ethanol for 5min→95% ethanol for 5min→80% ethanol for 5min→70% ethanol for 5min→wash with tap water for dewaxing. The dewaxed tissue slices were placed in hematoxylin for nuclear staining for 15min, the excess stain was washed off with tap water, and 1% hydrochloric acid ethanol was used for differentiation. After the excess differentiation solution was washed off with tap water, the slices were placed in eosin stain for cytoplasm for 5min, the excess stain was washed off with tap water, and the slices were sealed with neutral gum after dehydration.

[0104] 1.4.7 Statistical methods

[0105] SPSS25.0 was used for statistical analysis. Quantitative data were expressed as ±s, and qualitative data were expressed as percentages (%). Paired sample t-test was used for intra-group comparisons that met the normal distribution, and paired sample Kruskal-Wallis test was used for intra-group comparisons that did not meet the normal distribution. Independent sample t-test was used for inter-group comparisons that met the normal distribution, and Kruskal-Wallis test or chi-square test was used for inter-group comparisons that did not meet the normal distribution. One-way analysis of variance was used for comparisons between multiple groups that met the normal distribution, and Kruskal-Wallis test was used for comparisons between multiple groups that did not meet the normal distribution. P<0.05 indicated that the difference was statistically significant.

[0106] 2. Results

[0107] 2.1. Effects of Examples and Comparative Examples on Skin Lesions and Pathological Manifestations in Psoriasis Model Mice

[0108] 2.1.1. Effects of Examples and Comparative Examples on Skin Lesions in Psoriasis Mouse Model

[0109] After continuous drug administration, the skin photos of mice in each group are as follows: Figure 1 As shown. The skin of the mice in the blank group was smooth and showed a healthy flesh-pink color, without obvious accumulation and thickening of scales. In contrast, the epidermis of the skin of the mice in the model group was thickened, with more erythema and scales. The skin of the mice in Example 1-3 groups was slightly red and accompanied by a small amount of scales, but there was a significant improvement compared with the model group. Compared with Example 1 group, the skin of the mice in Comparative Example 2-3 groups showed more erythema and scales. Compared with Comparative Example 1 group, the skin of the mice in Example 1 group showed less scales.

[0110] The PASI scores of the back skin lesions of the blank group, model group, and Example 1-3 groups on the 6th day were statistically analyzed (see Figure 2), there were significant differences in the PASI scores of mice in each group. The results showed that the composition of Examples 1-3 improved the back skin lesions of psoriasis-like model mice and reduced their PASI scores.

[0111] The PASI scores of the back skin lesions of the mice in the blank group, model group, Example 1 group, and Comparative Example 1-3 groups on the 6th day were statistically analyzed (see Figure 3 ), there were significant inter-group differences in PASI scores between the mice in the comparative examples 1-3 groups and those in the example 1 group. The results showed that the composition of the example 1 was the best in improving the back skin lesions of the psoriasis-like model mice, and the PASI score of the mice in the example 1 group was the lowest.

[0112] 2.1.2 Effects of Examples and Comparative Examples on Pathological Manifestations of Psoriasis Mouse Model

[0113] Pathological examination showed that compared with the blank group mice, the stratum corneum and epidermis of the model group mice were significantly thickened, the spinous processes were thickened, the skin processes were elongated and undulated, the KCs were loosely arranged, and a large number of inflammatory cells infiltrated the dermis, which are typical pathological manifestations of psoriasis. The composition of Examples 1-3 can significantly improve the pathological manifestations of psoriasis in the model mice, as shown in FIG. Figure 4 .

[0114] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A Chinese medicine composition for treating psoriasis, characterized in that: The Chinese medicine composition consists of ephedra, cassia twig, red peony root, polygonum cuspidatum, artemisia annua and oldenlandia diffusa.

2. The Chinese medicine composition according to claim 1, characterized in that: The traditional Chinese medicine composition consists of 1-12 parts of ephedra, 3-18 parts of cassia twig, 3-18 parts of red peony root, 5-20 parts of knotweed, 5-40 parts of artemisia annua and 5-40 parts of oldenlandia diffusa by weight.

3. The Chinese medicine composition according to claim 2, characterized in that: The Chinese medicine composition consists of 6 parts of ephedra, 9 parts of cassia twig, 9 parts of red peony root, 10 parts of knotweed, 20 parts of artemisia annua and 20 parts of oldenlandia diffusa by weight.

4. The method for preparing the Chinese medicine composition according to any one of claims 1 to 3, characterized in that: The following steps are involved: Take ephedra, cinnamon twig, red peony root, knotweed, artemisia annua, and oldenlandia diffusa and grind them into powder.

5. A drug, characterized in that The effective ingredients of the medicine include the Chinese medicine composition according to any one of claims 1 to 3 or the Chinese medicine composition prepared according to the preparation method according to claim 4.

6. Use of the Chinese medicine composition according to any one of claims 1 to 3, the Chinese medicine composition prepared according to the preparation method according to claim 4, or the medicine according to claim 5 in the preparation of a medicine for treating psoriasis.

7. The use according to claim 6, characterized in that: The psoriasis is selected from any one of psoriasis vulgaris, psoriasis arthritis, psoriasis pustularis, and psoriasis erythroderma.

8. The use according to claim 7, characterized in that: The psoriasis is psoriasis vulgaris.

9. The use according to claim 6, characterized in that: The symptoms of psoriasis include: (1) Red patches appear on the skin, covered with silvery white scales; (2) Itching, burning or pain of the skin; (3) Dry, cracked or bleeding skin; (4) Scaly skin on the scalp; (5) The fingernails and / or toenails are pin-shaped or pitted, onycholysis, or subungual hyperkeratosis; (6) Joint swelling.

10. The use according to claim 9, characterized in that: The symptoms of psoriasis include: (1) Red patches appear on the skin, covered with silvery white scales; (2) Itching, burning or pain of the skin; (3) Dry, cracked or bleeding skin.

Images